Pemetrexed-erlotinib shows second-line efficacy in advanced NSCLC
Combination therapy with pemetrexed and erlotinib significantly improves progression-free survival as compared with either drug alone in patients with advanced non-squamous non-small-cell lung cancer, a phase II study has found.
Source: MedWire News - Oncology - Category: Cancer & Oncology Source Type: news
More News: Alimta | Cancer | Cancer & Oncology | Lung Cancer | Non-Small Cell Lung Cancer | Study | Tarceva